HUTCHMED, AstraZeneca Initiate Phase III Trial Of ORPATHYS& TAGRISSO In Certain Lung Cancer Patients

HUTCHMED (China) Limited (?HCM) and AstraZeneca Plc. (AZN,AZN.L) said that they have initiated SACHI, a China Phase III study of ORPATHYS (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor or "TKI", in combination with AstraZeneca's third-generation, irreversible epidermal growth factor receptor or "EGFR" TKI, TAGRISSO (osimertinib).

The companies stated that the first patient received their first dose on November 22, 2021.

The Phase III trial is a multi-center, open-label, randomized, controlled study in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer with MET amplification after disease progression on EGFR inhibitor therapy. The study will evaluate the efficacy and safety of ORPATHYS in combination with TAGRISSO, compared to platinum-based doublet-chemotherapy (pemetrexed plus cisplatin or carboplatin), the standard-of-care treatment option in the setting.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tyson Foods, Inc. (TSN) reported that its first quarter adjusted operating income declined 68% year-over-year. Adjusted operating margin was 3.4%, for the quarter. Both lower revenue and higher COGS in Beef and Pork drove the decrease in adjusted operating margin. The company said market dynamics... Baltimore, Maryland-based Fresh Ideation Food Group LLC is recalling certain sandwiches and other products sold under various brands, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for ready-to-eat or RTE stuffed chicken product citing that it may not be fully cooked due to underprocessing.
Follow RTT